Approaches for monitoring and treating cardiomyopathy among cancer survivors following anthracycline or thoracic radiation treatment
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2057-3804
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Approaches for monitoring and treating cardiomyopathy among cancer survivors following anthracycline or thoracic radiation treatment ; volume:8 ; number:1 ; day:12 ; month:5 ; year:2022 ; pages:1-9 ; date:12.2022
Cardio-Oncology ; 8, Heft 1 (12.5.2022), 1-9, 12.2022
- Urheber
-
Delavar, Arash
Boutros, Catherine
Barnea, Dana
MD, Wendy L. Schaffer
Tonorezos, Emily S.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40959-022-00138-x
- URN
-
urn:nbn:de:101:1-2022071719223439015151
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Delavar, Arash
- Boutros, Catherine
- Barnea, Dana
- MD, Wendy L. Schaffer
- Tonorezos, Emily S.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction: Approaches for monitoring and treating cardiomyopathy among cancer survivors following anthracycline or thoracic radiation treatment
Myeloperoxidase is a critical mediator of anthracycline-induced cardiomyopathy
Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
Electrocardiograms for cardiomyopathy risk stratification in children with anthracycline exposure
Increasing survivors of anthracycline-related cardiomyopathy with breast cancer in trastuzumab era: thirty-one-year trends in a Japanese Community
Sexual Issues in Treating Trauma Survivors
Molecular pathogenetic mechanisms and new therapeutic perspectives in anthracycline-induced cardiomyopathy
Extracellular matrix remodeling in animal models of anthracycline-induced cardiomyopathy: a meta-analysis
Anthracycline-induced hypertension in pediatric cancer survivors: unveiling the long-term cardiovascular risks
Early markers of cardiovascular injury in childhood leukaemia survivors treated with anthracycline chemotherapy
Resting and exercise arterial dysfunction in anthracycline-treated adult survivors of childhood cancers
Evaluating anthracycline cardiotoxicity associated single nucleotide polymorphisms in a paediatric cohort with early onset cardiomyopathy
Correction: Approaches for monitoring and treating cardiomyopathy among cancer survivors following anthracycline or thoracic radiation treatment
Myeloperoxidase is a critical mediator of anthracycline-induced cardiomyopathy
Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
Electrocardiograms for cardiomyopathy risk stratification in children with anthracycline exposure
Increasing survivors of anthracycline-related cardiomyopathy with breast cancer in trastuzumab era: thirty-one-year trends in a Japanese Community
Sexual Issues in Treating Trauma Survivors
Molecular pathogenetic mechanisms and new therapeutic perspectives in anthracycline-induced cardiomyopathy
Extracellular matrix remodeling in animal models of anthracycline-induced cardiomyopathy: a meta-analysis
Anthracycline-induced hypertension in pediatric cancer survivors: unveiling the long-term cardiovascular risks
Early markers of cardiovascular injury in childhood leukaemia survivors treated with anthracycline chemotherapy
Resting and exercise arterial dysfunction in anthracycline-treated adult survivors of childhood cancers
Evaluating anthracycline cardiotoxicity associated single nucleotide polymorphisms in a paediatric cohort with early onset cardiomyopathy
Correction: Approaches for monitoring and treating cardiomyopathy among cancer survivors following anthracycline or thoracic radiation treatment
Myeloperoxidase is a critical mediator of anthracycline-induced cardiomyopathy
Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
Electrocardiograms for cardiomyopathy risk stratification in children with anthracycline exposure
Increasing survivors of anthracycline-related cardiomyopathy with breast cancer in trastuzumab era: thirty-one-year trends in a Japanese Community
Sexual Issues in Treating Trauma Survivors
Molecular pathogenetic mechanisms and new therapeutic perspectives in anthracycline-induced cardiomyopathy
Extracellular matrix remodeling in animal models of anthracycline-induced cardiomyopathy: a meta-analysis
Anthracycline-induced hypertension in pediatric cancer survivors: unveiling the long-term cardiovascular risks
Early markers of cardiovascular injury in childhood leukaemia survivors treated with anthracycline chemotherapy
Resting and exercise arterial dysfunction in anthracycline-treated adult survivors of childhood cancers